Variant renal cell carcinoma histologies: Therapeutic considerations

Daniel M. Geynisman; Walter M. Stadler

doi:10.1007/978-3-642-21858-3_17

Variant renal cell carcinoma histologies: Therapeutic considerations

Daniel M. Geynisman, Walter M. Stadler

University of Chicago

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Non-clear cell renal cell carcinoma (NCCRCC) accounts for approximately 20–25% of all cases of renal epithelial cancers, and a significant proportion of those patients present with advanced disease. Once a patient has metastatic NCCRCC, survival is worse compared to those with metastatic clear-cell RCC, but this may not be true across all specific subtypes. More importantly, almost all clinical trials examining therapeutic options in metastatic renal cell carcinoma have excluded non-clear cell patients and thus little level one data exist regarding the most appropriate treatment options. In this chapter, we review the histologic, genetic, and molecular features of this diverse entity of cancer as well as the survival implications for patients. Following this, we explore the data behind the use of conventional chemotherapy, immunotherapy, VEGF pathway, and mTOR-targeted therapy in NCCRCC.

Original language	English
Title of host publication	Kidney Cancer
Subtitle of host publication	Principles and Practice
Publisher	Springer Berlin Heidelberg
Pages	249-264
Number of pages	16
ISBN (Electronic)	9783642218583
ISBN (Print)	9783642218576
DOIs	https://doi.org/10.1007/978-3-642-21858-3_17
State	Published - Jan 1 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-642-21858-3_17

Cite this

@inbook{dbf6741316f54fb490392264ecda51d7,

title = "Variant renal cell carcinoma histologies: Therapeutic considerations",

abstract = "Non-clear cell renal cell carcinoma (NCCRCC) accounts for approximately 20–25% of all cases of renal epithelial cancers, and a significant proportion of those patients present with advanced disease. Once a patient has metastatic NCCRCC, survival is worse compared to those with metastatic clear-cell RCC, but this may not be true across all specific subtypes. More importantly, almost all clinical trials examining therapeutic options in metastatic renal cell carcinoma have excluded non-clear cell patients and thus little level one data exist regarding the most appropriate treatment options. In this chapter, we review the histologic, genetic, and molecular features of this diverse entity of cancer as well as the survival implications for patients. Following this, we explore the data behind the use of conventional chemotherapy, immunotherapy, VEGF pathway, and mTOR-targeted therapy in NCCRCC.",

author = "Geynisman, {Daniel M.} and Stadler, {Walter M.}",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag Berlin Heidelberg 2012.",

year = "2012",

month = jan,

day = "1",

doi = "10.1007/978-3-642-21858-3_17",

language = "English",

isbn = "9783642218576",

pages = "249--264",

booktitle = "Kidney Cancer",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Variant renal cell carcinoma histologies

T2 - Therapeutic considerations

AU - Geynisman, Daniel M.

AU - Stadler, Walter M.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Non-clear cell renal cell carcinoma (NCCRCC) accounts for approximately 20–25% of all cases of renal epithelial cancers, and a significant proportion of those patients present with advanced disease. Once a patient has metastatic NCCRCC, survival is worse compared to those with metastatic clear-cell RCC, but this may not be true across all specific subtypes. More importantly, almost all clinical trials examining therapeutic options in metastatic renal cell carcinoma have excluded non-clear cell patients and thus little level one data exist regarding the most appropriate treatment options. In this chapter, we review the histologic, genetic, and molecular features of this diverse entity of cancer as well as the survival implications for patients. Following this, we explore the data behind the use of conventional chemotherapy, immunotherapy, VEGF pathway, and mTOR-targeted therapy in NCCRCC.

AB - Non-clear cell renal cell carcinoma (NCCRCC) accounts for approximately 20–25% of all cases of renal epithelial cancers, and a significant proportion of those patients present with advanced disease. Once a patient has metastatic NCCRCC, survival is worse compared to those with metastatic clear-cell RCC, but this may not be true across all specific subtypes. More importantly, almost all clinical trials examining therapeutic options in metastatic renal cell carcinoma have excluded non-clear cell patients and thus little level one data exist regarding the most appropriate treatment options. In this chapter, we review the histologic, genetic, and molecular features of this diverse entity of cancer as well as the survival implications for patients. Following this, we explore the data behind the use of conventional chemotherapy, immunotherapy, VEGF pathway, and mTOR-targeted therapy in NCCRCC.

UR - http://www.scopus.com/inward/record.url?scp=84956841409&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-21858-3_17

DO - 10.1007/978-3-642-21858-3_17

M3 - Chapter

AN - SCOPUS:84956841409

SN - 9783642218576

SP - 249

EP - 264

BT - Kidney Cancer

PB - Springer Berlin Heidelberg

ER -

Variant renal cell carcinoma histologies: Therapeutic considerations

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this